ResearcherWashington University in St. LouisNo recent work listed
Jake E.J. Krige
Matched on ORCID iD 0000-0002-7057-9156; OpenAlex author ID A5047252741. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2021: 6 papers
Papers 6
- Neoadjuvant chemotherapy for non-metastatic pancreatic cancer. Last author DOI 10.1002/jhbp.935↗
- Letter to the Editor: Comment on: Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. First author DOI 10.1007/s12029-021-00656-4↗
- Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB analysis. Last author DOI 10.1016/j.ejca.2021.09.001↗
- Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and … Co-author DOI 10.1016/j.hpb.2020.09.022↗
- Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000004877↗
- Translation and linguistic validation of the EORTC QLQ-PAN26 questionnaire for assessment of health-related quality of life in patients with pancreatic cancer … Co-author DOI 10.17159/2078-5151/2021/v59n4a3487↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eduard Jonas · 6 shared papers, 2021 · strength 1.14
- Paper Neoadjuvant chemotherapy for non-metastatic pancreatic cancer. DOI 10.1002/jhbp.935↗
- Paper Letter to the Editor: Comment on: Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combin… DOI 10.1007/s12029-021-00656-4↗
- Paper Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB ana… DOI 10.1016/j.ejca.2021.09.001↗
- Jessica D. Lindemann · 4 shared papers, 2021 · strength 0.76
- Paper Neoadjuvant chemotherapy for non-metastatic pancreatic cancer. DOI 10.1002/jhbp.935↗
- Paper Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB ana… DOI 10.1016/j.ejca.2021.09.001↗
- Paper Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancrea… DOI 10.1097/sla.0000000000004877↗
- Marc M. Bernon · 3 shared papers, 2021 · strength 0.57
- Paper Letter to the Editor: Comment on: Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combin… DOI 10.1007/s12029-021-00656-4↗
- Paper Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB ana… DOI 10.1016/j.ejca.2021.09.001↗
- Paper Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal … DOI 10.1016/j.hpb.2020.09.022↗
- Urda K. Kotze · 2 shared papers, 2021 · strength 0.32
- Paper Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal … DOI 10.1016/j.hpb.2020.09.022↗
- Paper Translation and linguistic validation of the EORTC QLQ-PAN26 questionnaire for assessment of health-related quality of … DOI 10.17159/2078-5151/2021/v59n4a3487↗
- K.J. Gqada · 1 shared paper, 2021 · strength 0.16
- Christo Kloppers · 1 shared paper, 2021 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.